Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: First or Second Line HER2-negative Breast Cancer|Metastatic Disease Without Bone Metastasis
Interventions: DRUG: Zoledronic acid|DRUG: Standard Therapy
Sponsor: Novartis Pharmaceuticals